REGN - Regeneron Pharmaceuticals, Inc.

NasdaqGS - NasdaqGS Real-time price. Currency in USD
-13.34 (-2.18%)
At close: 4:00PM EDT

606.05 +6.58 (1.10%)
Pre-market: 8:00AM EDT

Stock chart is not supported by your current browser
Previous close612.81
Bid593.31 x 1000
Ask610.00 x 800
Day's range597.62 - 609.66
52-week range271.37 - 615.36
Avg. volume1,601,628
Market cap61.575B
Beta (5Y monthly)0.53
PE ratio (TTM)30.11
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
Press releases
  • GlobeNewswire

    Regeneron and Zai Lab Announce Regional Strategic Collaboration for REGN1979 (CD20xCD3 Bispecific Antibody)

    Regeneron Pharmaceuticals, Inc. (REGN) and Zai Lab Limited (ZLAB) today announced a strategic collaboration for the development and commercialization of REGN1979 (CD20xCD3 bispecific antibody) in mainland China, Hong Kong, Taiwan and Macau. The collaboration will support global clinical development for REGN1979, starting with the ongoing potentially registrational Phase 2 program in B-cell non-Hodgkin lymphoma (B-NHL). Additionally, if REGN1979 is approved, Zai Lab will leverage its capabilities to commercialize REGN1979 in this region.